Background: In 2006, dual-eligible nursing home residents were randomly assigned to a Medicare Part D prescription drug plan (PDP).
Part D's implementation, dual-eligible residents received drug coverage from Medicaid. At the time of Part D's inception, all dual-eligible residents were randomized to one of the multiple Part D prescription drug plans (PDPs) serving dual eligibles in their region, that is, plans with premiums at or below the regional benchmarks. Subsequently, individuals enrolled in plans that lost benchmark status or left the market were rerandomized to another plan. Because PDPs vary with respect to coverage and utilization management requirements for specific medications, a dual-eligible resident may be randomly assigned to a plan that is relatively more or less generous for the drugs that the individual is taking.
The impact of PDP generosity on a nursing home resident's medication use is not currently known. Evidence from both Medicaid enrollees and privately insured individuals suggests that coverage restrictions and utilization management tools like prior authorization and step therapy result in medication changes and discontinuation and can lead to higher hospitalization rates and higher health-care spending. [11] [12] [13] [14] [15] [16] [17] [18] There is also evidence that medication changes and discontinuations in an elderly nursing home population can lead to adverse drug events, hospitalization, or death. [19] [20] [21] Part D, however, includes special protections for dual-eligible nursing home residents: longer transition fill policies that allowed PDPs to fill prescriptions for noncovered drugs while alternate therapies were considered; no beneficiary cost sharing; and the ability to change PDPs monthly.
We assessed the impact of PDP coverage and utilization management on medication use, hospitalization, and death among dual-eligible nursing home residents. We relied on the randomization of residents to PDPs to address the potential selection bias that is common in observational studies of how plan generosity affects use. We focused on 6 medication classes that are commonly used in this population and often subject to PDP coverage limitations. 10 
METHODS
Our study population included dual-eligible nursing home residents aged 65 or older, who resided in facilities that contract with Omnicare, a long-term care pharmacy serving over 60% of nursing home residents in the United Sates, to dispense prescription medications. We linked data from 2005 to 2008 from: drug claims from Omnicare; demographic characteristics from Medicare Beneficiary Summary Files; dates of hospitalizations from MedPAR; death date from the Minimum Data Set; and PDP formulary coverage and utilization management requirements from the CMS Prescription Drug Plan Formulary and Pharmacy Network Files. We excluded individuals who died on January 1 of the year in question or who did not have at least 1 Minimum Data Set assessment (used to confirm the date of death).
We focused on 2 groups of residents: (1) those residing in nursing homes at the time Part D was implemented and thus randomized to a PDP with enrollment effective from January 1, 2006, and (2) those randomized to a new plan effective from January 1, 2007, or from January 1, 2008, because their prior plans' premium bids exceeded regional benchmarks. For 2007 and 2008, we excluded individuals who elected to change plans in the previous year, as these individuals were not automatically rerandomized when their current plan lost benchmark status. We pooled individuals rerandomized for 2007 and 2008 because of smaller sample sizes and the consistency of transition policies that applied to nursing home residents during those 2 years compared with 2006.
We focused on residents currently using a medication in 1 of the following 6 classes as of January 1 during each year: angiotensin receptor blockers (ARBs), cholinesterase inhibitors, long-acting opioids, osteoporosis medications, antidepressants, and antipsychotics. Antidepressants and antipsychotics are "protected classes," meaning that plans must cover at least 1 formulation of every molecule. For the other 4 classes, plans are required to cover at least 1 molecule. We define "current users" as those who filled at least 2 prescriptions in the class with 10 or more days of supply each or 3 prescriptions with any number of days supplied during the 100 days before enrollment on January 1 of the year in question. The median number of days supplied for prescriptions in each medication class and year were 28 to 30, with the exception of opioids, with a median of 15 days. To ensure interpretable drug class-level outcomes, we excluded the small proportion of individuals who were currently using >1 drug in the class during the 100-day period (eg, in 2006, <8% for all classes except antidepressants, which was 19.6%).
We examined 4 outcomes. First, we assessed medication changes within the class, identified by a prescription claim for a drug in the class other than the drug that the resident was currently taking during the 100 days before January 1. Changes between brand and generic formulations of the same drug (eg, brand paroxetine tablet to generic paroxetine tablet) were not considered as a "change." Among individuals who changed, we also assessed the proportion of residents who subsequently had a prescription claim for their original preperiod drug.
Second, we identified gaps in use within the class of 31 or more days (eg, no antidepressants for 31 or more days). Outcomes were measured from January 1 to 240 days later for 2006 current users and from January 1 to 150 days later for 2007 and 2008 current users. We selected the window's duration to account for the transition policies in place each year allowing residents to continue current medications regardless of the PDP coverage rules (up to 210 days in 2006 and 120 days in 2007 and 2008), with an additional 30 days for drug supply to be exhausted after the transition policy ends. 22 For individuals who were hospitalized or died, we truncated the windows at the date of hospitalization or death. If a resident experienced both a medication change and a gap in use during the period, we counted only the event that occurred first.
Third, we assessed whether a resident was hospitalized in the year after enrollment in the randomized plan. Finally, we identified deaths within the year after an individual's enrollment in the randomized plan.
The 2 main independent variables are whether the resident's current medication was not covered (vs. covered) by the new PDP to which the resident was randomized and whether the PDP required prior authorization or step therapy if the drug was covered (vs. covered without these limits). We combined prior authorization and step therapy into a single variable, as plans typically use one tool or the other for a given drug but not both.
Models were adjusted for the following covariates: resident age as of January 1; male (vs. female); nonwhite (ie, "black" or "other" vs. white); region (midwest, northeast, or south, vs. west); and dummy variables for the drug the resident was taking before randomization. For pooled 2007 and 2008 models, we included a binary variable indicating 2007 enrollment (2008 is the reference category).
We estimated logistic regression models for each outcome by drug class and year and then calculated the average probability of each outcome under each coverage restriction (noncoverage and prior authorization/step therapy), adjusted for the covariates noted above. To transform estimates from the log-odds ratios under the logistic regression model to an easily understood metric, we estimated the average probability (or "risk") of each outcome for a given coverage restriction by evaluating the fitted regression model, supposing that every patient was assigned or not assigned that restriction and then averaging the results across patients. The difference in the resulting average-estimated probability is an average risk difference. These analyses included residents who could have been current users across >1 of the 6 medication classes. We were unable to estimate models for 2007 and 2008 antipsychotic users because of the small number of individuals whose antipsychotic medication was uncovered.
A concern with analyzing 4 outcomes (medication change, gap in use, hospitalization, and death) and testing the effect of 2 benefit design measures (noncoverage and prior authorization/step therapy) for each of the 6 drug classes, yielding 48 tests in total (not accounting for any stratification of the data across years), is that the chance of finding a significant result when in fact none exists is much higher than the 0.05 level of a single test. We used the Bonferroni correction to correct for the fact that we are conducting multiple tests. 23 Using this correction, a P value in any test must exceed 0.00104 to report a significant finding to be assured that the test has a level no greater than 0.05.
As a robustness check, we estimated survival models of the number of days to a medication change, adjusting for the same covariates used in the logistic regression models. An advantage of fitting the survival models is that we accounted for differential amounts of follow-up of individuals, which could lead to bias.
RESULTS
Our sample included 92,813 dual-eligible residents who were current users of 1 or more of the 6 classes for 2006 and 32,315 current users as of 2007 or 2008 (Table 1) .
Only a minority of current users faced noncoverage of their medication or prior authorization or step therapy, although these rates varied across classes ( Table 2 ). For example, for the 2006 group, noncoverage rates varied from 0.4% (antipsychotics and osteoporosis medications) to 8.7% (opioids), whereas prior authorization/step therapy rates for covered drugs varied from 1.9% (antidepressants) to 13.5% (cholinesterase inhibitors).
Medication changes were much more likely among residents with noncovered drugs than those whose drug was covered after adjusting for individual-level covariates for 4 of 6 classes in 2006 and for 4 of 5 classes in 2007 and 2008 (all but antipsychotics and opioids in 2006 and opioids in 2007 and 2008, for which there were no statistically significant differences after correcting for multiple comparisons). For example, among 2006 ARB current users, the adjusted risk of medication change was 0.35 among those with noncovered drugs versus 0.11 among those with covered drugs (Pr0.0001; Table 3 ). Similarly, gaps in use were more likely among residents whose current drug was uncovered than among those whose drug was covered for 4 of 6 classes in 2006 (all but osteoporosis medications and antipsychotics, for which there was no statistically significant difference) and 2 of 5 classes in 2007 and 2008 (all but cholinesterase inhibitors, osteoporosis medications, and opioids, with no statistically significant differences) ( Table 3 ). We exclude individuals who used >1 medication in the class in the 100 days before randomization to a new plan. Individuals may be current medication users of >1 drug class, so the sum of current users across the 6 classes exceeds the total number of individuals in the study population (ie, 92,813 in 2006 and 32,315 in 2007 and 2008).
Among residents whose current medication was covered by their new PDP, those whose drug required prior authorization or step therapy were more likely to change medications than those without such requirements within 2 of the 6 classes in 2006 (all but opioids, for which residents without prior authorization/step requirements were sig-nificantly more likely to change than those with such requirements, and antipsychotics, cholinesterase inhibitors, and antidepressants, with no statistically significant difference) and 3 of the 6 classes in 2007 and 2008 (all but ARBs, antidepressants, and opioids, with no statistically significant differences) ( Table 3 ). Gaps in use were more likely among those with prior authorization or step therapy requirements than those without for 2 of the 6 classes in 2006 (all but opioids, antidepressants, osteoporosis medications, and antipsychotics, with no statistically significant differences) and 0 of the 6 classes in 2007 and 2008.
A sizeable proportion of residents who changed medications after enrollment in their new PDP subsequently had a claim for the original medication they had been taking previously (Table 4 ). In 2006, for instance, 54%, 53%, and 46% of opioid, antidepressant, and antipsychotic current users, respectively, who changed medications after randomization later filled a prescription for their preperiod drugs.
After correcting for multiple comparisons, there were no statistically significant differences in hospitalization or death rates based on either coverage or prior authorization or step therapy (conditional on coverage).
Results from the survival models of time to medication change were similar to results on the probability of a medication change using logistic regression models (see online Technical Appendix for detail, Supplemental Digital Content 1, http://links.lww.com/MLR/A523). For parsimony and ease of interpretation, we presented only the adjusted rates derived from the logistic regression models. We excluded individuals who used >1 medication in the class in the 100 days before randomization to a new plan. Current medication users for 2007 and 2008 were pooled.
ARB indicates angiotensin receptor blockers; PA, prior authorization. Prior authorization and step therapy are only required for covered drugs, so we assess whether prior authorization or step therapy was required conditional on plan coverage. We were unable to estimate models for atypical antipsychotic users in 2007 and 2008 because of a very small number of individuals whose atypical antipsychotic medication was not covered by their new plan.
*Results that remain statistically significant after correcting for multiple comparisons using the Bonferroni correction. ARB indicates angiotensin receptor blockers.
DISCUSSION
Random assignment to plans with differing levels of coverage and utilization management requirements influenced prescribing patterns for elderly dual-eligible nursing home residents.
Our findings suggest higher rates of medication use disruptions among residents facing Part D coverage restrictions for their drugs relative to similar residents not facing such restrictions. We found at least some evidence of medication disruptions resulting from coverage policies in every medication class studied, including Part D "protected" classes (antidepressants and antipsychotics) and nonprotected classes (ARBs, cholinesterase inhibitors, opioids, and osteoporosis medications), and classes with a relatively higher (eg, ARBs) versus lower (eg, antidepressants) degree of therapeutic similarity. Interestingly, the higher rates of medication use disruptions did not appear to lead to higher rates of hospitalizations or deaths in this frail elderly population.
Our study extends prior research describing the effects of Part D implementation. These previous studies generally have documented increased medication use, lower out-ofpocket spending, and lower nondrug medical utilization and expenditures after implementation. [24] [25] [26] [27] [28] [29] [30] [31] [32] However, almost all of these studies have focused on community-dwelling beneficiaries. Of studies specific to nursing home residents, one found that Part D implementation resulted in a small decrease in the average number of prescriptions filled among long-stay residents in 2006 relative to 2005. 33 A study of 569 case histories collected by email from nursing home clinicians about post-Part D medication changes for nonmedical reasons found that approximately 75% reflected decreased efficacy after the change. 34 Our analyses are shaped by features of how Part D works in the nursing home setting. Perhaps, most important for our study design, all dual-eligible residents nationwide were randomly assigned to PDPs in 2006, and 1.1 million and 2.1 million were rerandomized in 2007 and 2008, respectively, due to their plans losing benchmark status or leaving the Part D market. 35 Random assignment enabled us to assess the effects of coverage on use independent of unobserved patient characteristics that could influence treatment and plan choice in observational studies.
Beyond the randomized plan assignment, several policy features likely influenced our findings. First, federal regulations required nursing homes to provide all care included in residents' care plans regardless of coverage. Consequently, residents may be somewhat buffered against adverse coverage provisions. Moreover, this regulatory requirement may be further reinforced by communication challenges between pharmacy staff, PDPs, and prescribing clinicians, who often operate off-site. 10 Together, these factors may partially explain why many residents facing coverage restrictions did not change drugs or experience a gap. Nonetheless, because facilities must absorb the cost of noncovered medications in the care plans, these regulations give facilities a strong incentive to encourage physicians to change to a drug not subjected to restrictions. A second policy unique to the nursing home setting is the CMS's guidance on transition policies (described previously), serving to further protect residents from medication changes that can result from coverage determinations. Third, residents do not face medication copayments and thus have no direct incentives to choose drugs preferred by their PDP. As a result, plans rely solely on formulary coverage and utilization management to influence use among residents. Finally, 2 of the 6 protected classes, antipsychotics and antidepressants, are commonly used among residents nationwide. 36, 37 Although these policies are likely influential, they are not necessarily determinate. Despite coverage restrictions, especially noncoverage, being relatively modest overall, they nonetheless affected the use. The fact that patterns of changes and gaps among those facing restrictions were found both for drugs in protected and nonprotected classes suggests that the protections may not ensure that all formulations needed by nursing home residents (eg, dissolvable tablets, solutions) are available or possibly that utilization management could negatively affect access in some cases. If policymakers determine that access in certain protected classes was problematic for residents, Part D policies could be modified (eg, CMS could require coverage of specific medications or formulations).
Although our findings focused on dual-eligible nursing home residents, they have broader implications for other Part D populations. First, dual eligibles living in the community or congregate settings like assisted living facilities face similar assignment dynamics to randomly assigned duals in nursing homes (ie, some are randomized to plans where their drugs are covered less well) without the nursing homeÀ specific protections. Moreover, unlike nursing home residents, duals living in other settings are additionally affected by cost sharing (between $1.15 and $6.60 per prescription for generic and brand medications, respectively).
Some have argued for an alternative plan assignment process that would consider the medications residents are currently taking, attempting to match beneficiaries to PDPs with relatively generous coverage of those drugs. For example, in late 2005, Maine officials used a "beneficiary-centered assignment" process that considered formulary coverage to reassign nearly half of the state's dual eligibles. 38 Random assignment was adopted initially with the hope of ensuring adequate PDP participation; participating plans would be guaranteed an equal share of dual-eligible beneficiaries and a random draw of health risks (ie, individuals with high vs. low drug expenditures). If formulary coverage of residents' medications was considered in plan assignment, plans might have an incentive to avoid covering medications used by residents with a relatively higher drug spending if the risk adjustment system did not adequately account for these differences, which in practice it did not. 39 Although only a few states have adopted beneficiary-centered assignment, they have reported no market disruptions resulting from it. 40 More broadly, some have criticized the reliance of Part D on a consumer choice À oriented model for beneficiaries living in nursing homes. 10 The underlying premise is that informed consumers will choose the plan that best meets their needs and that competition among plans will be spurred as a result. Although randomized initially, dual eligibles are permitted to change plans monthly, for example, if particular PDPs are not well matched to their needs. However, the high prevalence of cognitive impairment in this population undermines the potential for informed decision-making, and many residents do not have engaged family members or responsible parties to assist them with these choices. In addition, Federal regulations restrict the ability of nursing homes to direct residents to particular PDPs to minimize a facility's ability to steer residents in financially beneficial ways.
Prescription drug claims lack detailed clinical information on beneficiaries' health status and functioning. As a result, we are not able to identify the indications for which drugs were used, comorbidities that could have influenced use, or outcomes. Although we found no statistically significant differences in the rates of hospitalizations or death after correcting for multiple comparisons, it may be that cognitive and functional outcomes are the more relevant clinical outcomes affected by Part D coverage restrictions. Our data cover the first 3 years of Part D implementation. Reports have documented an increased use of utilization management tools like prior authorization among PDPs since our study period, and plan practices may have evolved over time. 41 Our study lack data on how strictly utilization management is applied by PDPs (eg, the proportion of residents who sought prior authorization who obtain it). Strengths of our study include the large national sample of dual-eligible nursing home residents; the ability to link data on prescription drug use and PDP coverage; and the randomization of residents to PDPs.
The Part D benefit represented a substantial departure from how prescription drugs had been financed and administered to dual-eligible nursing home residents. Our findings show that coverage and utilization management rules can result in higher rates of medication changes and gaps in use, even in so-called "protected classes" like antidepressants and antipsychotics. At the same time, the Part D benefit offers many special protections for nursing home residents that potentially ameliorate the health impact of PDP coverage limits on this frail population, something for which our analyses offer initial, confirmatory evidence. Nonetheless, the impact of Part D coverage policies on the health and functioning of frail elderly nursing home residents should be monitored going forward, both to assess the impact of coverage policies on a range of more targeted outcomes and to ensure that the changing PDP marketplace continues to meet the needs of this frail population.
